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Abstract
Background: According to the surveillance system in Turkey, most diseases are notified only by clinicians, without
involving laboratory notification. It is assumed that a considerable inadequacy in notifications exists; however, this
has not been quantified by any researcher. Our aim was to evaluate the completeness of communicable disease
surveillance in the province of Izmir, Turkey for the year of 2003 by means of estimating the incidences of diseases.
Methods: Data on positive laboratory results for the notifiable and serologically detectable diseases hepatitis A, B,
C, brucellosis, syphilis, measles and HIV detected in 2003 in Izmir (population 3.5 million) were collected from
serology laboratories according to WHO surveillance standards and compared to the notifications received by the
Provincial Health Directorate. Data were checked for duplicates and matched. Incidences were estimated with the
capture-recapture method. Sensitivities of both notifications and laboratory data were calculated according to
these estimates.
Results: Among laboratories performing serologic tests (n = 158) in Izmir, 84.2% accepted to participate, from
which 23,515 positive results were collected. Following the elimination of duplicate results as well as of cases
residing outside of Izmir, the total number was 11,402. The total number of notifications was 1802. Notification
rates of cases found in laboratories were 31.6% for hepatitis A, 12.1% for acute hepatitis B, 31.8% for brucellosis,
25.9% for syphilis and 100% for HIV confirmation.
Conclusions: It was discovered that for hepatitis A, B, C, brucellosis and syphilis, there is a considerable under-
notification by clinicians and that laboratory data has the potential of contributing greatly to their surveillance. The
inclusion of laboratories in the surveillance system of these diseases could help to achieve completeness of
reporting.
Background
Laboratory notification has become an integral part in
the surveillance system of many countries as a result of
advances in laboratory diagnosis. According to the com-
municable disease surveillance system in Turkey, most
diseases are expected to be notified only by clinicians,
without involving laboratory notification. This route
leads to significant under-estimation of disease burden.
According to a study carried out on hepatitis A cases in
a paediatric state hospital in Izmir in 1999, only 30.2%
of the 351 cases with a positive IgM antiHAV laboratory
result were reported [1]. Although these data existed in
the laboratory of the hospital, they were not sent to the
local health authority as there was no such chain of
notification defined and as there is a considerable
underreporting by clinicians.
The objectives of this study were:
1. To assess completeness of surveillance of some
notifiable diseases by combining laboratory data and
notifications.
2. To quantify under-notification using capture-
recapture.
3. To evaluate the contribution of laboratory data to
notifications in order to give recommendations on how
laboratory data can best improve the surveillance system
in Turkey.
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Scope
According to the communicable disease surveillance sys-
tem in operation during the study, there were 39 notifi-
able diseases [2]. For practicality in data collection,
diseases having serological diagnostic procedures
according to WHO surveillance standards [3] were
selected: hepatitis A, B, C, brucellosis, syphilis, measles
and HIV/AIDS. The results of the serological para-
meters shown in Table 1 were collected as data.
All the province of Izmir (nine urban and 19 rural dis-
tricts) with its 3.5 million inhabitants was covered in
this research since inhabitants of a district could be
diagnosed in other districts with more numerous and
sophisticated medical facilities. The city of Izmir, admin-
istrative centre of the province, is the third largest
metropolitan area of Turkey and with two university
hospitals and six other public tertiary care hospitals,
there would be little chance for cases to be diagnosed
elsewhere. By procedure, notifications from all districts
are sent to Izmir Provincial Health Directorate, enabling
comparison at a provincial level.
In order to contact all serology laboratories in the
province, the list of public and private facilities provid-
ing laboratory services was obtained from the provincial
health directorate. All these facilities were visited (n =
190) in search for laboratories using serological diagnos-
tic procedures. Facilities not applying serology (n = 21)
and facilities which were no longer in operation (n =
11) were excluded. Facilities measuring at least one of
the serological parameters stated in Table 1 were the
target group of the study (n = 158).
Data collection and analysis
Data on cases that were diagnosed in the year 2003 were
collected between 21 January 2003 and 25 March 2005.
A total of 133 serology laboratories (84.2%) agreed to
participate in the study. Table 2 shows the distribution
of facilities performing serological tests in Izmir accord-
ing to their agreeance to participate, their locations and
their types.
Data concerning cases having positive serology results
in 2003 were collected from participating laboratories.
Most of these data were actively collected on consecu-
tive visits: Cases were found by scanning records, usually
on paper/laboratory notebooks and information about
their identities was traced among administrative records,
usually in a computer system. In some laboratories
where results were not retained and there were few
cases identified, we left case report forms for the labora-
tory to complete. Facilities were also asked to send elec-
tronic notifications to the researcher. Some laboratories
Table 1 Serological parameters used in the study for data collection
Disease WHO serological criteria [3] Additional criteria and relevance
Hepatitis A IgM anti-HAV positive (acute) -
Hepatitis B HBsAg positive (unspecified) or IgM anti-HBc positive (acute) Total anti-HBc positive when IgM Anti-HBc not tested
HBV-DNA positive
Hepatitis C anti-HCV positive (acute and unspecified combined) HCV-confirmation positive
HCV-RNA positive, showing also infectivity
Brucellosis
a Brucella agglutination titre (e.g., standard tube agglutination >
160) or ELISA (IgA, IgG, IgM), 2-ME (confirmed)
Rose-Bengal test, due to its use as a screening test (probable)
Syphilis RPR or VDRL confirmed by TPHA or FTA -
Measles
b Specific IgM antibodies -
HIV infection HIV positive serology (ELISA), confirmation HIV-RNA positive
a For brucellosis, complement fixation, FAT and RIA for detecting antilipopolysaccharide antibodies also exist among WHO criteria but as these tests were not
being performed in any laboratory in Izmir, they are not used as criteria.
b For measles, “at least a fourfold increase in antibody titre and virus isolation” is also stated among WHO criteria. But as it would not be practical to follow-up
the first criteria and as virus isolation was not performed in any laboratory in Izmir, these criteria were not used.
Table 2 Locations, type and acceptance status of facilities
performing serological tests in Izmir province
Accepted Rejected Total
n % n % n % among
total
Total in the urban area 92 80.0 23 20.0 115 72.8
Total public 26 92.9 2 7.1 28 17.7
Hospital 19 95.0 1 5.0 20 12.7
Blood donation
centre
a
4 80.0 1 20.0 5 3.2
Laboratory 3 100.0 - 3 1.9
Total private 66 75.9 21 24.1 87 55.1
Hospital 9 90.0 1 10.0 10 6.3
Laboratory 57 74.0 20 26.0 77 48.7
Total out of the urban area 41 95.3 2 4.7 43 27.2
Total public 17 94.4 1 5.6 18 11.4
Hospital 15 100.0 - 15 9.5
Blood donation
centre
1 100.0 - 1 0.6
Laboratory 1 50.0 1 50.0 2 1.3
Private laboratory 24 96.0 1 4.0 25 15.8
Total 133 84.2 25 15.8 158 100.0
a The four cooperating centres are part of hospitals but are classified as
separate facilities due to difference in their test procedures.
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ities were also visited for data collection, as some of
them did not send electronic notifications although they
had agreed to.
Laboratory results and notifications were entered into
the same database. The database included one row for
each laboratory test day for cases found positive. Data
were matched based on full name, and for similar
names additional data including date of birth, sex,
father’s name, address, phone number, date of testing
and diagnosis were used to match cases. Duplicates in
multiple laboratories were classified according to the
laboratory which first diagnosed them. For HIV/AIDS,
both data sources did not include names but were
coded with a standard process relying on surname,
name, father’s name and birth year. Cases were com-
pared according to these standard codes and only a
100% match on the code was used to link records.
As notifications to Izmir Provincial Health Directorate
consisted only of cases residing in Izmir, laboratory -
diagnosed cases not residing in Izmir also needed to be
removed from the analysis. To do this, cases with miss-
ing addresses were classified as cases from Izmir if they
were found positive out of the urban area or in second-
ary care institutions inside the metropolitan area (6.5%
of cases), since cases with a referral sent from other pro-
vinces to Izmir are cared for in tertiary care institutions.
Cases with a missing address in tertiary care (25.1% of
cases) were assigned randomly as Izmir or non-Izmir
cases, proportionate to the number of non-Izmir cases
found in each institution among cases with known
addresses. Laboratory diagnosis rates and reported rates
were calculated using numbers of cases found in each
source and 2003 mid-year population of Izmir province.
Application of the capture-recapture method
Capture-recapture is a method used to estimate the
number of individuals in a population using population-
based data from two or more independent, but overlap-
ping sources [4]. Its name deriving from its first usage
by zoologists, it has been used in human populations
since 1949 [5,6]. In recent years, it has been used by epi-
demiologists to estimate prevalence or incidence of sev-
eral diseases, to evaluate completeness of different
notifications and to estimate coverage of cancer regis-
tries [4,7-11]. The underlying reason for its usage is the
insufficiency of disease surveillance systems in covering
all cases and its appropriateness, as a method, in cor-
recting this insufficiency [12,13].
Incidence rates were calculated using Izmir’s mid-year
population in 2003. Incidences and sensitivity of notifi-
cations were estimated with capture-recapture method
using two data sources: cases found positive in labora-
tories and cases notified. Estimates were calculated with
Chapman’s formula developed for two-list capture-
recapture [6] and Chao’s lower bound estimator using
f r e q u e n c yd a t aa d a p t e df o rat w o - s o u r c ec a p t u r e - r e c a p -
ture [14]. Both formulas are given below.
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Where f1 is the frequency of those identified by
exactly one source (equal to [L1+L2-2d]i nC h a p m a n ’s
formula), and f2 the frequency of identifications by
exactly two sources (equal to [d]).
Ethical considerations
A written permission was received from the Ministry of
Health. Ethical committee approval was obtained from a
local tertiary care hospital providing graduate medical
education.
The anonymity and security of identities of cases was
of major importance in this study. The confidentiality of
data was guaranteed to participating facilities and to
TÜBİTAK; the institution granting this research. Data
were collected by only one researcher who entered and
stored it in a password-protected database.
Results
Among laboratories performing serological tests, 93.5%
public (n = 46) and 80.4% private (n = 112) facilities
accepted to participate in the study (Table 2).
Data were collected thoroughly from 77.4% (n = 103)
of the participating institutions for the year 2003. In
5.3% of the facilities (n = 7), data could not be obtained
due to the lack of record-keeping. In 7.5% (n = 10) data
on some months were missing, in 6.8% (n = 9) data for
some months could not be accessed due to unsolvable
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were closed in the year 2003 so data were available only
for the months they were open.
Internet connection was available in 42.1% (n = 56) of
participating facilities, among which 44.6% (n = 25)
accepted to send electronic notifications to the
researcher. Only four facilities sent electronic notifica-
tions. Another facility sent the addresses of cases elec-
tronically. No positive case was found in four of the 20
facilities which did not send electronic notifications.
In total, 628 visits were made to participating facilities
and data concerning 19,458 positive results were col-
lected. With the addition of 4057 (17.3%) positive results
sent electronically, the total number of positive results
collected during this study amounted to 23,515. Among
positive results, 93.2% were diagnosed in public versus
6.8% in private institutions and 89.2% were diagnosed in
hospitals, 7.1% in laboratories and 3.7% in blood dona-
tion centres. Among all positive results, 80.4% were
diagnosed in only 11 public institutions (8.6% of facil-
ities) of which 68.4% consisted of positive results for
hepatitis B. In 20.9% (n = 27) of the facilities, no
positive result was found and all of these were private
laboratories.
After the elimination of duplicates, 23515 positive
results corresponded to 17319 cases. Among these,
11402 cases were classified as cases from Izmir. For the
same period, 1802 cases were notified to the directorate
for the same diseases, 488 of them common in total.
The distribution and quantity of cases found in labora-
tories and the notifications are displayed in Table 3
based on different levels of parameters. Notification
rates of cases found in laboratories and reported rates
are shown in the same table. Notification rates of cases
found in laboratories were the highest for HIV (100%),
about one third for hepatitis A, brucellosis and syphilis,
12% for acute hepatitis B and 1-4% for hepatitis C.
Explanations for the use of different levels of parameters
are discussed below in the paragraphs related to each
disease. Table 4 shows capture-recapture estimates of
the total numbers of cases, sensitivities of each source
and incidence estimates.
For hepatitis B, the number of cases meeting WHO
criteria was 10285, compared with 225 notifications. As
Table 3 Numbers of cases of each disease and notification rates in Izmir, 2003 (N = 3,506,672)
No. of records in the data sources Rates according to data sources
(per 100,000)
Lab
diagnoses
(a)
Notifications
to Health
Directorate
(b)
Matched
records
(c)
Proportion of lab
diagnoses notified
% (c/a)
Lab
diagnosis
rate (a/N)
Notification
rate
(b/N)
Combined
rate
([a+b-c]/N)
Hepatitis A 560 587 177 31.6 15.97 16.74 27.66
Hepatitis B
WHO criteria 10285 225 157 1.5
IgM anti-HBc 380 225 46 12.1 10.84 6.42 15.94
Hepatitis C
WHO criteria 148 89 2 1.4
Hepatitis C total 2271 89 75 3.3
Dialysis & gastroenterology
cases omitted
1757 89 75 4.3 50.10 2.54 50.50
Brucellosis
WHO criteria 151 116 48 31.8 4.31 3.31 6.25
Agglutination ≤ 1/80 307 116 65 21.2 8.75 3.31 10.21
Syphilis
WHO criteria 201 86 52 25.9 5.73 2.45 6.70
notified lab cases not meeting
WHO criteria included
217 86 68 31.3 6.19 2.45 6.70
Measles 5
a 272 0 0 0.14 7.76 7.87
HIV
Confirmation or RNA positive 23 15 6 26.1 - 0.17 -
Confirmation or RNA positive,
previous years’ notifications
included
23 154
b 23
b 100.0 - - -
Total 11402 1802 488 4.3 - - -
a One of the positive cases is due to vaccination
b Notifications of previous years included
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Turkey is an intermediate-endemic country for Hepatitis
B [15], a second analysis was performed with IgM anti-
HBc positive cases only, yielding 380 cases diagnosed in
laboratories and an incidence estimate (Tables 3, 4).
Among the hepatitis C cases discovered in labora-
tories in Izmir, few met WHO criteria (n = 148), with
only two of them present among notifications. A further
analysis was conducted including all anti-HCV positive
cases (Tables 3, 4). At least 14.1% (n = 320) of cases
found in laboratories were dialysis patients, 14.1% (n =
320) were found positive during blood donor testing,
and 8.5%(n = 194) were admitted to a gastroenterology
unit. The admitting unit was not known in 22.8% of
cases. The dialysis patients in particular were regularly
tested serologically at two-month intervals. Of the anti-
HCV positive cases found during blood donor testing,
18.8% (n = 60) were notified and constituted the major-
ity of notifications (n = 89). As none of the dialysis/gas-
troenterology cases were notified, they were omitted and
a third analysis was conducted with the remaining 1757
cases to prevent a much higher capture-recapture esti-
mate due to possible negative dependence.
Among brucellosis cases, 25.1% (n = 151) met WHO
criteria. Some laboratories had used cut-off 1/80 for
agglutination, which was also preferred by some authors
[16], so a second analysis was performed using this cut-
off, which included more of the notified cases in the
analysis (Tables 3, 4).
Among syphilis notifications, 79.1% (n = 68) were
present on the laboratory list but only 52 of them con-
formed to WHO criteria.
As none of the five measles cases discovered in
laboratories were notified, a capture-recapture estimate
was not calculated. Of the 272 cases notified, 76.5%
were diagnosed in primary health centres where there is
no laboratory testing for measles.
For HIV/AIDS, there were 206 positive cases detected
in laboratories according to WHO criteria of which 54
were notified. As a serological parameter showing acute/
recent infection is lacking for HIV/AIDS -as well as for
hepatitis C-cases found positive in laboratories might be
cases that were diagnosed in previous years. It was possi-
ble to check previous years’ notifications for HIV/AIDS,
but not for hepatitis C. In total 168 cases were estimated
to be from Izmir of which 10 of them were notified in
2003 and a further 24 notified in previous years. As many
anti-HIV affirmations could be cases of false-positive
[17], and as only confirmed cases are notified as a rule in
Izmir, only the results of confirmed cases (confirmation
or RNA positive) are shown in Table 4, giving a notifica-
tion rate of 100% when compared with all (2003 or ear-
lier) HIV/AIDS notifications. Since 100% of cases were
notified, a capture-recapture estimate was not calculated.
Discussion
This study provides evidence of considerable underre-
porting of hepatitis, brucellosis and syphilis in Izmir,
Table 4 Capture-recapture estimates of total numbers of cases, sensitivities of each source, incidence estimates and
95% confidence intervals
Chapman’s formula Chao’s lower bound estimator
Total number of
cases in
population
Sensitivity
lab %
Sensitivity
notifications
%
Incidence
(per
100,000)
Total number of
cases in
population
Sensitivity
lab%
Sensitivity
notifications
%
Incidence
(per
100,000)
Hepatitis A 1852
(1665-2040)
30
(28-34)
32
(29-35)
52.8
(47.5-58.2)
1858
(1669-2047)
30
(27-34)
32
(29-35)
53.0
(47.6-58.4)
Hepatitis B
IgM anti-HBc 1831
(1399-2263)
21
(17-27)
12
(10-16)
52.2
(39.9-64.5)
1989
(1502-2477)
19
(15-25)
11
(9-15)
56.7
(42.8-70.6)
Hepatitis C
dialysis &
gastroenterology
omitted
2081
(1901-2260)
84
(78-92)
4
(4-5)
59.3
(54.2-64.5)
11359
(8997-13721)
15
(13-20)
1
(1-1)
323.9
(256.6-
391.3)
Brucellosis
WHO criteria 362
(299-425)
42
(36-51)
32
(27-39)
10.3
(8.5-12.1)
371
(304-439)
41
(34-50)
31
(26-38)
10.6
(8.7-12.5)
Agglutination < 1/80 545
(468-622)
56
(49-66)
21
(19-25)
15.5
(13.4-17.7)
688
(572-804)
45
(38-54)
17
(14-20)
19.6
(16.3-22.9)
Syphilis
WHO criteria 331
(283-378)
61
(53-71)
26
(23-30)
9.4
(8.1-10.8)
396
(327-465)
51
(43-61)
22
(19-26)
11.3
(9.3-13.3)
notified lab cases not
meeting WHO
criteria included
274
(250-298)
79
73-87)
31
(29-34)
7.8
(7.1-8.5)
338
(293-382)
64
(57-74)
25
(23-29)
9.6
(8.4-10.9)
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of cases diagnosed in laboratories and the potential con-
tribution of laboratory data to their surveillance was sig-
nificant. Official rates of disease were less than 1/3 to 1/
8 of incidences estimated. Surveillance of HIV/AIDS
was satisfactory with 100% of confirmed cases notified.
As few facilities actually sent electronic notifications to
the researcher, it might be premature to implement
electronic notifications in the surveillance system.
Strengths and limitations of the study
This study has the strength of comparing the contribu-
tion of laboratory data to notifications in the surveil-
lance of different diseases in Izmir. This is the first
comprehensive study on the evaluation of completeness
of communicable disease surveillance in Turkey through
collection of data from a source independent of the
ministry’s official notifications.
As Izmir is a referral centre for Aegean Region, the
design was convenient for covering cases from Izmir.
This study could not have been conducted in another
province in the region since there would have been
many cases applying to facilities in Izmir for secondary
and tertiary care, reducing coverage of local cases.
Data were collected thoroughly in 77.4% of participat-
ing facilities. As for the remainder, inaccessibility to data
for the first 3.5 months of 2003 of a tertiary care hospi-
tal (one of the six facilities with > 1000 positive results)
and lack of data from the virology department of a pub-
lic health laboratory of the ministry (a facility contribut-
ing with 97 positive results for brucellosis and syphilis
with its bacteriology department) are considered as an
important limitation of the study. Another limitation is
t h em i s s i n gr e s i d e n c ef o ro n ef o u r t ho fc a s e si nt e r t i a r y
care, which could have caused some misclassification
when eliminating cases out of Izmir.
Among the non-participating facilities, lack of hepati-
tis B and C cases from one public blood donation centre
is considered to be significant. The other non-participat-
ing facilities are not considered to cause much limitation
since most of them are small-scale private laboratories
which would have found only 1-5 positive results
throughout the year or no positive result at all.
Another limitation is the use of different serological
test procedures with different sensitivities and specifici-
ties for the same parameter in different laboratories,
possibly leading to some false positive and false negative
results which cannot be controlled due to the lack of
clinical data in this study. This has also caused carrier
or chronic cases to be on the la b o r a t o r yl i s t .T h es u r -
veillance system in operation in 2003 did not have any
case definitions for notifications, so carrier cases were
also found among notifications, along with probable
cases.
Accuracy of capture-recapture analysis
There are four main assumptions that should be eval-
uated before implementing a capture-recapture analy-
sis [6]. The province of Izmir can be considered a
closed population. However; during the course of the
research which covered the whole of the year 2003,
there might have been some in- or out- migration
from the city, which would have falsified to a small
degree the assumption that the population is a closed
one.
Theoretically, the two lists could be positively depen-
dent, since the notification probability of a case diag-
nosed in laboratory could be greater. Chronic cases or
cases with severe disease are more likely to be notified
[18]. Positive dependence would result in the calculation
of a smaller estimate, thus estimation of a higher com-
pleteness of notifications [6,9,18]. Inaccessibility to the
first 3.5 months’ data of a tertiary care hospital might
have created negative dependence since the cases noti-
fied from that hospital in that period do not have the
possibility of being on the laboratory list, if not also
diagnosed elsewhere. This problem is not anticipated
for the virology department of the public health labora-
t o r ys i n c et h e yd on o tn o t i f ya n yd i s e a s ee x c e p tH I V /
AIDS. However; some of the few cases notified by pri-
mary health centres might have been diagnosed in this
laboratory. Overall, when this study was conducted,
laboratory confirmation was not required for notifying a
case, and as the results show, notifications and labora-
tory reports are almost independent samples, combined
with the considerable underreporting of laboratory
cases. For hepatitis C, some of the cases found in labs
could have been cases from previous years, leading to
some negative dependence and thus a considerably high
estimate.
As for the assumption on equal catchability, this
might have been affected by the lack of data in some
participating facilities and laboratories that did not
accept to participate in the study, both of which are dis-
cussed above.
Capture-recapture results according to both methods
are similar when the number of cases appearing on both
lists is relatively higher. When different, estimates calcu-
lated according to Chapman’s formula can be consid-
ered more cautiously, while Chao’s method might be
more realistic if there is an underestimation due to
some positive dependence.
Possible mechanisms and implications
This study has showed that there is a considerable
underreporting of infectious diseases in Izmir. A similar
underreporting might be expected for the whole of Tur-
key, with official reported rates 9.64 and 7.3 per 100,000
for hepatitis A and B [19], much lower than incidences
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most developed provinces where incidences might be
expected to be lower. The reported incidence of 20.30
per 100,000 for brucellosis in Turkey might also need
caution in interpretation [19], considering its underre-
porting rate in Izmir.
This study has also showed that laboratory data can
make an important contribution to the surveillance
system of these diseases classified as Group A in the
new system [20]. According to the new communicable
disease surveillance system introduced as of the begin-
ning of 2005, most of the notifiable diseases are classi-
fied as Group A which are notified by clinicians as in
the previous system and laboratories are not involved
in this passive surveillance [21]. Only a limited number
of pathogens classified as Group D are reported by
laboratories (Shigella, Salmonella, EHEC, Campylobac-
ter, Listeria monocytogenes, Entamoeba histolytica,
Cryptosporidium, Giardia intestinalis and Chlamydia
trachomatis). The only changes in the system for
group A diseases are the introduction of standard case
definitions and the classification of cases as confirmed/
probable. The reason why a considerable proportion of
cases notified have not been diagnosed in laboratories
could be the lack of case definitions in the previous
system.
Among types of facilities, hospitals were significant
w i t ht h ed i a g n o s t i cr a t eo f8 9 %o fa l lp o s i t i v er e s u l t s .
The public sector played an important role in the diag-
nosis of these diseases through a contribution of 93%
of all positive results. A strategy to improve complete-
ness could be the active surveillance of the few public
facilities with the highest numbers of positive results.
Completeness of reporting could also be achieved by
making it mandatory to report diagnoses from all
laboratories.
For measles, the low number of cases diagnosed in
laboratories and the high percentage of notifications
from primary health centres implies the importance of
clinical diagnosis and the lack of standard case defini-
tions. Its reported rate is consistent with the incidences
of measles in Turkey (8.1 per 100000) [19]. When inci-
dence decreases with increasing control of disease, it
becomes important to confirm suspected cases [22]. In
former East Germany with very high vaccine coverage
and incidence rates lowered to 0.7 per 100,000, 71% of
notified cases were laboratory-confirmed compared with
34% in former West Germany with an incidence rate of
8.7 per 100,000 [23]. As Measles Elimination Pro-
gramme has started in 2002 in Turkey, laboratory data
can be expected to become more important in following
years [24].
According to official incidences, Izmir could be classi-
fied as a low endemicity zone like Europe for hepatitis
A while with the addition of cases discovered in labora-
tories, its incidence occurrence level becomes intermedi-
ate, like Turkey in general [25].
This study required an enormous effort to collect data
which will never be feasible for routine surveillance.
Methods for capturing these data could be computer
queries to capture positive cases among laboratory
results [26,27], and/or active surveillance in the few
large-scale facilities where most cases occur.
Conclusions
This is the first study quantifying completeness of com-
municable disease surveillance in Turkey. A consider-
able underreporting of hepatitis, brucellosis and syphilis
has been found while surveillance of HIV was satisfac-
tory. Mandatory laboratory based surveillance of com-
municable diseases should be incorporated into the
surveillance system. If this is not possible, active surveil-
lance could be carried out in a few large-scale tertiary
public laboratories to capture most of the cases. Further
research is also required to investigate the false positive
test results and reasons of under-notification by
clinicians.
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